
1st International Electronic Conference on Biomedicine
Part of the International Electronic Conference on Biomedicines series
1–26 Jun 2021
Therapeutic Targets, Therapeutic Strategies, Naturally Driven Biomedicines, Pharmaceuticals, Biopharmaceutical Products
- Go to the Sessions
-
- S1. Nanomedicine and Precision Medicine
- S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- S3. Cancer Therapeutics
- S4. Metal-based Therapeutics in Preclinical and Clinical Developments
- S5. Oncolytic Virus-Mediated Immunotherapy
- S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- S10. G-protein-coupled Receptor Family
- S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
- Event Details
ECB 2021 has been a success! Welcome to the new electronic conference ECB 2023.
Welcome from the Chairs
Dear Colleagues,
It is my pleasure to invite you to join the 1st International Electronic Conference on Biomedicine (ECB 2021) that is hosted online by: https://ecb2021.sciforum.net.
ECB 2021 will present the latest research related to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products.
Topics of interest include but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 seeks to fulfill this need by offering a completely digital (online) method for running a scientific conference. ECB 2021 will allow its participants to share their latest research results and receive near-instantaneous feedback from biomedical researchers throughout the world through online question and answer sessions and discussion groups. In this way, ECB 2021 will serve as a platform for advancing the state-of-the-art in biomedicines. There is no cost to participate in ECB 2021.
All submitted abstracts will be evaluated by the conference committee. Upon acceptance of their abstract, authors will contribute an extended abstract for the conference proceedings and a slide presentation of their work. Selected papers (need 50% extension compared with the proceedings papers) will be considered for publication in the special issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)", with a 20% discount on the APC after peer-review.
I hope you will choose to be a part of this exciting conference and present your most transformative research on biomedicine.
Conference Secretariat
Ms. Nicole Peng
MDPI Branch Office, Wuhan
E-mail: [email protected]
Ms. Penny Zhang
MDPI Branch Office, Wuhan
E-mail: [email protected]
Ms. Stefanie Li
MDPI Branch Office, Wuhan
E-mail: [email protected]
Conference Chairs

Albany College of Pharmacy and Health Sciences, Rensselaer, USA

Faculté de Pharmacie, Paris, France
Conference Committee

Albany College of Pharmacy and Health Sciences, Rensselaer, USA

The University of Auckland, Auckland, New Zealand

The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA

McMaster University, Ontario, Canada

University of Szeged, Szeged, Hungary

The London BioScience Innovation Centre, London, United Kingdom

Alborg University, Aalborg, Denmark

The University of British Columbia, Vancouver, Canada

Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Session Chairs

Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA
Nanomedicine and Precision Medicine; Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals

Dr. Veronique Baud
Faculté de Pharmacie, Paris, France
Cancer Therapeutics

Dr. Muhammad Hanif
The University of Auckland, Auckland, New Zealand
Metal-based Therapeutics in Preclinical and Clinical Developments

Dr. Zong Sheng Guo
The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA
Oncolytic Virus-Mediated Immunotherapy

Dr. Jacek M. Kwiecien
McMaster University, Ontario, Canada
Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure

Dr. Masaru Tanaka
University of Szeged, Szeged, Hungary
Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry

Professor Alexander Seifalian
The London BioScience Innovation Centre, London, United Kingdom
Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants

Dr. Allan Stensballe
Alborg University, Aalborg, Denmark
Translational Biomarkers in Clinical Biomedicine and Precision Medicine

Professor Ujendra Kumar
The University of British Columbia, Vancouver, Canada
G-protein-coupled Receptor Family

Professor Ciro Isidoro
Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Invited Speakers

1. Department of Surgery, Drexel University College of Medicine, Pittsburgh, PA 15212, USA
2. AHN Cancer Institute
Sessions
S1. Nanomedicine and Precision MedicineS2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S3. Cancer Therapeutics
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
S5. Oncolytic Virus-Mediated Immunotherapy
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Video from Invited Speaker
Oncolytic Virus-Mediated Immunotherapy
by Prof.Dr. David Bartlett
List of accepted submissions (50)
Id | Title | Authors | Presentation Video | Presentation Pdf | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-044011 | Antidepressant-like Effects of Kynurenic Acid Analogues | , , , , , |
![]() |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Kynurenic acid (KYNA) is a metabolite of the L-tryptophan (TRP)-kynurenine (KYN) pathway which has been shown to possess neuroprotective and antidepressant-like properties. The intracerebroventricular (i.c.v.) administration of kynurenic acid (KYNA) triggered antidepressant-like effects at least in part through the serotonin 5-hydroxytryptamine (5-HT) type 2 receptors, D2, D3, D4 dopamine receptors, and gamma-aminobutyric acid subunit A (GABAA) receptors in modified forced swimming test (FST) of mouse. However, KYNA is impermeable to the blood-brain-barrier (BBB) and thus it is probably a cause that the peripheral administration of KYNA did not exhibit an antidepressant-like effect. New KYNA analogues were designed to overcome the BBB in attempt to deliver neuroprotective KYNA molecules to the central nervous system (CNS). The antidepressant-like effects of KYNA analogues SZR-72, SZR-81, and SZR-104 were studied i.c.v. and intraperitoneally (i.p.) with a modified FST. The FST revealed that i.c.v. administration of SZR-81 significantly decreased immobility and significantly increased swimming time, which suggested that its antidepressant-like effects were triggered through the serotonin 5-HT nervous system. SZR-72 and SZR-104 did not significantly change either immobility, climbing, or swimming time, suggesting SZR-72and SZR-104 did not have antidepressant-like effects. Furthermore, i.p. administration of SZR-81 did not change either immobility, climbing, or swimming time like i.c.v. administration. Two of the KYNA analogues SZR-72and SZR-104 may not have the antidepressant-like properties and SZR-81 may not cross the BBB or be modified on the way to the CNS. Novel KYNA analogues are expected to be designed in search of potent antidepressants which reserve antidepressant properties, cross the BBB, and target in the CNS. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044843 | Self-Nano Emulsifying Drug-Delivery Systems: From the Development to The Current Applications and Update of the Biopharmaceutical Aspect | , |
![]() |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Approximately one-third of newly discovered drug molecules show insufficient water solubility and therefore low oral bioavailability. Different lipid-based formulations have been explored in the past few decades to improve the oral delivery of such compounds. Self-nano-emulsifying drug-delivery systems (SNEDDSs) are one of the emerging strategies developed to tackle the issues associated with their oral delivery. Self-Nano-emulsifying drug delivery systems (SNEDDS), which are isotropic mixtures of oils, surfactants, solvents, and co-solvents/surfactants, can be used for the design of formulations in order to improve the oral absorption of highly lipophilic drug compounds. The efficiency of oral absorption of the said drug from such type of formulation depends on many formulation-related parameters, such as surfactant concentration, oil/surfactant ratio, the polarity of the emulsion, droplet size, and charge, all of which in essence determine the self-emulsification ability. With the growing interest in this field, there is an increasing need for the selection of excipients guidelines to obtain an effective and safe delivery system with improved bioavailability. The aim of this review is to present the mechanism of self-emulsification, composition, the role of various excipients, formulation approaches, different techniques, evaluation parameters, factors affecting SNEDDS, advantages, drawbacks, applications, and future trends. This review also offers an updated overview of SNEDDS application from the biopharmaceutical point of view, various techniques used for the transformation of liquid SNEDDS into solid dosage forms, and regulatory status of SNEDDS. The present review gives an insight into SNEDDS for the oral administration of both lipophilic and hydrophilic compounds. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044681 | A Potential Role of Hypoxia-Inducible Factor (Hif-1) Alpha in Taravana Syndrome | , , , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
The number of subjects who practice recreational breath-hold diving is increasing; therefore there is a growing need to know the adaptations that this sport could have on the health of the participants. They are exposed to an increased hyperbaric pressure and low temperature that cause change in arterial blood gases and induced a human diving response which includes increased arterial blood pressure, reduced cardiac output, bradycardia and peripheral vasoconstriction. Start on the matter that these adaptations are still not fully understood, we decided to investigate some biomarkers that should be involved in this disorders starting to analyse Hypoxia-inducible factor 1 alpha (HIF-1a). We enrolled in our study 31 healthy free divers from different part of Sicily, aged 41,86 ± 11,41, weight 77,52 ± 11,30 kg, height 175,19 ± 6,13 cm, who practiced this activity for more than 5 years. We asked them to perform 5 consecutive dives at 20 meters, without permanence on the bottom, with free recovery between the different dives. A baseline venous blood sample was taken immediately after surfacing from the 5th dive (less than 3 minutes). The samples were stored to -80 until the analysis were done using ELISA method. The results showed that comparing HIF-1a value before and after the dives, there were an increase in the concentration that started from 158,43 pg/ml and be at end 246,06 pg/ml. In conclusion, the Hypoxia-inducible factor 1 alpha can be considered co-responsible for various phenomena, certainly not with pathological destinies, but rather working with "adaptation" phenomena to this type of activity. These are just the preliminary results that need further investigations to be confirmed. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044790 | Blood compatibility of originally synthesized amphiphilic dendrons | , , , , , , , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Dendrons and dendrimers are nanoscale polymer molecules with unique hyperbranched structure. The high number of functional groups enable these polymers to be easily modified further, thus creating potential for use as therapeutics. Their interactions with biological systems are mainly predetermined by their chemical structure, terminal groups, surface charge and by the number of branched layers (i.e. generation). Blood compatibility is a mandatory requisite for the safe intravenous administration of drug-loaded nanoparticles. In this work, we assessed the interactions of originally synthesized amphiphilic phosphorous dendrons with whole human blood. We investigated changes in more than dozen hematological and some coagulation parameters upon addition of the first and second generation dendrons at the lower and upper limits of the concentration range (2-10 µM) examined in our previous experiments. We found significantly decreased number of platelets associated with a significant increase in the activated partial thromboplastin time for the combination of higher concentration and the 2nd generation dendron. Viewing blood films under the light microscope confirmed occasional platelets clumps in this experimental condition. Findings at other conditions were not associated with any clinical significance from a hematological point of view. Our data indicate that thrombogenic propensity might not be the only issue in the nanomedicine safety. Coagulation abnormalities may also relate to prolonged clotting time – presumably as a result of induced consumption of clotting factors and/or platelets. In vitro assays using human blood appear to be a suitable tool to study mechanisms of dendron-based nanomedicines interference with hemostasis and to optimize their hemocompatibility. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-041442 | TCGA PanCanAtlas data analysis suggests multiple possibilities for personalized cancer therapy |
Aleksey Belikov ,
,
,
|
N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Personalized cancer medicine holds promise for the future of cancer treatment. The key to success is the knowledge of exact molecular alterations that drive tumorigenesis in a given patient, so that a suitable targeted therapy can be selected. However, the extent of such alterations, i.e. number of various kinds of driver mutations per patient, is still not known. We have utilized the largest database of human cancer mutations – TCGA PanCanAtlas, multiple popular algorithms for cancer driver prediction and several custom scripts to estimate the number of various kinds of driver mutations in primary tumors. We have found that there are on average 19.6 driver mutations per patient’s tumor, of which 2.4 are hyperactivating SNA mutations in oncogenes, 9.2 are CNA amplifications of oncogenes, 0.6 have both in the same oncogene, 0.2 are homozygous inactivating SNA mutations in tumor suppressors, 1.1 have inactivating SNA mutation in one allele and CNA deletion in the other allele of a tumor suppressor, 1.5 are driver chromosome losses, 2 are driver chromosome gains, 1 is driver chromosome arm loss, and 1.6 are driver chromosome arm gains. The number of driver mutations per tumor gradually increased with age, from 12.5 for <25 y.o. to 23.6 for >85 y.o. There was no big difference between genders (19.9 in males vs 19.2 in females). The number of driver mutations per tumor varied strongly between cancer types, from 1.5 in thyroid carcinoma to 43 in lung squamous cell carcinoma. Overall, our results provide valuable insights into the extent of driver alterations in tumors and suggest that multiple possibilities to choose a suitable targeted therapy exist in each patient. |
Instructions for Authors
Submissions should be submitted by the authors online by registering at https://ecb2021.sciforum.net/, and using the “Submit Abstract” function once logged into system.
- Scholars interested in participating with the conference can submit their abstract (about 200–250 words covering the areas of manuscripts for the proceedings issue) online at this website up to 16 March 2021.
- The Conference Committee will conduct a pre-evaluation, based on the submitted abstract, of whether the contribution from the authors of the abstract will be welcome for the 1st International Electronic Conference on Biomedicine. All authors will be notified by 31 March 2021 about the acceptance of their abstract.
- If the abstract is accepted for this conference, the author is asked to submit the manuscript optionally along with a PowerPoint and/or video presentation of his/her paper (only PDF), up to the submission deadline of 30 April 2021.
- The conference proceedings papers and presentations will be available at https://ecb2021.sciforum.net for discussion during the time of the conference, 1–26 June 2021, and will be published in Journal Proceedings.
- After the conference, the authors are encouraged to submit a full manuscript based on the proceedings to the Biomedicines Special Issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)" with a 20% discount on the Article Processing Charges.
Manuscripts for the proceedings issue must have the following organization:
First page:
- Title
- Full author names
- Affiliations (including full postal address) and authors’ e-mail addresses
- Abstract (200–250 words)
- Keywords
- Introduction
- Methods
- Results and Discussion
- Conclusions
- (Acknowledgements)
- References
Manuscripts should be prepared in MS Word or any other word processor and should be converted to PDF format before submission. The publication format will be PDF. The manuscript should be at least 3 pages (incl. figures, tables, and references) and should not exceed 6 pages.
Presentation Slides
Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides, if available, will be displayed directly in the website using the proprietary slides viewer at Sciforum.net. Slides can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to PDF format before submission so that we can easily and automatically process them for online display.
Video Presentations
Besides their active participation within the forum, authors are also encouraged to submit video presentations. The video should be no longer than 20 minutes and be prepared in one of the following formats:
- MOV
- MPEG4
- MP4
- AVI
- WMV
- MPEGPS
- FLV
Authors that wish to present only a poster, i.e., without a proceedings paper, can do so in section I. Posters will be available on the conference website during and after the event. Similarly to papers presented at the conference, participants will be able to ask questions and make comments about the posters. Posters that are submitted without a paper will not be included in the proceedings of the conference.
Submission: Manuscripts should be submitted online at https://ecb2021.sciforum.net by registering and logging in to this website.
Accepted File Formats
- MS Word: Manuscript prepared in MS Word must be converted into a single file before submission. When preparing manuscripts in MS Word, the 1st International Electronic Conference on Microbiology Microsoft Word template file (see download below) must be used. Please do not insert any graphics (schemes, figures, etc.) into a movable frame which can superimpose the text and make layout very difficult.
1st International Electronic Conference on Biomedicine Microsoft Word template file
Manuscript Preparation
- Paper Format: A4 paper format, the printing area is 17.5 cm × 26.2 cm. The margins should be 1.75 cm on each side of the paper (top, bottom, left, and right sides).
- Paper Length: The conference proceedings paper should not be longer than 6 pages. The conference manuscript should be as concise as possible.
- Formatting/Style: The paper style of the journal Proceedings should be followed. You may download the template file to prepare your paper (see above). The full titles of the cited papers must be given. Reference numbers should be placed in square brackets [ ], and placed before punctuation; for example [4] or [1–3], and all the references should be listed separately and as the last section at the end of the manuscript.
- Authors List and Affiliation Format: Authors’ full first and last names must be given. Abbreviated middle name(s) can be added. For papers written by various contributors, a corresponding author must be designated. The PubMed/MEDLINE format is used for affiliations: complete street address information including city, zip code, state/province, country, and email address should be added. All authors who contributed significantly to the manuscript (including writing a section) should be listed on the first page of the manuscript, below the title of the article. Other parties who provided only minor contributions should only be listed under Acknowledgments. A minor contribution might be a discussion with the author, reading through the draft of the manuscript, or performing English corrections.
- Figures, Schemes, and Tables: Authors are encouraged to prepare figures and schemes in color. Full color graphics will be published free of charge. Figure and schemes must be numbered (Figure 1, Scheme I, Figure 2, Scheme II, etc.) and an explanatory title must be added. Tables should be inserted into the main text, and numbers and titles for all tables supplied. All table columns should have an explanatory heading. Please supply legends for all figures, schemes, and tables. The legends should be prepared as a separate paragraph of the main text and placed in the main text before a table, figure, or scheme.
Potential Conflicts of Interest
It is the authors’ responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state here “The authors declare no conflict of interest”. This should be conveyed in a separate “Conflict of Interest” statement preceding the “Acknowledgments” and “References” sections at the end of the manuscript. Financial support for the study must be fully disclosed under the “Acknowledgments” section.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a Communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Call for Papers
The 1st International Electronic Conference on Biomedicine will be held on 1–26 June 2021. ECB 2021 aims to promote and advance the exciting and rapidly changing field of Biomedicine. All proceedings will be held online at https://ecb2021.sciforum.net.
Topics of interest include, but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 is an electronic conference sponsored by Biomedicines. Participation is free of charge for authors and attendees. Accepted papers will be gathered in the proceedings of the conference. Selected extended versions of the papers will be published in a Special Issue of Biomedicines and undergo full peer review (ISSN 2227-9059; impact factor: 4.717 (2020)) with a 20% discount on the article processing charge. ECB 2021 offers you the opportunity to participate in this international, scholarly conference without the concerns or expenditure of travel—all you need is your computer and access to the internet. We would like to invite you to attend this conference and present your latest work.
Abstracts (in English) should be submitted online by 16 March 2021 at https://ecb2021.sciforum.net. For accepted abstracts, the proceedings can be submitted by 30 April 2021. The conference will be held on 1–26 June 2021.
Paper Submission Guidelines
For information about the submission procedure and preparation of a full presentation, please refer to the "Instructions for Authors".
Time Schedule
- Abstract Submission: 16 March 2021
- Notification of Acceptance: 31 March 2021
- Paper Submission Deadline: 30 April 2021
- Conference Open: 1–26 June 2021
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Event Awards
To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to launch the Best Paper Award and Best Poster Award.
The Awards
The Best Paper Award is presented to the paper judged to make the most significant contribution to the conference.
The Best Poster Award was established to recognize the scientific merit exhibited in poster presentation and preparation.
Terms and Conditions:
Best Paper Award
As a sponsor, Biomedicines would like to award the best paper as elected by the conference committee. The award will consist of 500 Swiss Francs. We look forward to posting your contributions.
Criteria for Evaluation of Best Paper Award:
- Full paper must be submitted to ECB2021;
- Originality/novelty of the paper;
- Significance of content;
- Scientific soundness;
- Interest to the readers;
- English language and style.
Evaluation
- Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above;
- The total score for each presentation will be ranked from highest to lowest;
- If two or more authors receive the same score, further evaluation will be carried out;
- All decisions made by the Evaluation Committee are final.
Best Poster Award
As a sponsor, Biomedicines would like to grant an award (500 Swiss Francs) for the best poster presented at the conference. This prize is awarded by a jury to the best designed poster presented at the conference.
Posters should have the following information.
- Title (with authors and affiliations)
- Introduction/Objectives/Aims
- Methods
- Results
- Conclusion
- References
- Acknowledgements
- Contact information
- A 3-minute video presentation
During the conference, the chair is invited to judge the quality of the 3-minute video presentation and poster. Criteria for judgement of the presentation will be the ability to summarize the content of the work and motivate the interest in looking at the poster. In addition, the clarity of poster and appearance quality will be considered.
S1. Nanomedicine and Precision Medicine
S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
Session Chair
Dr. Muhammad Hanif, The University of Auckland, Auckland, New Zealand
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
Show all published submissions (7) Hide published submissions (7)
Submissions
List of Papers (7) Toggle list